WebJul 17, 2024 · FIGHT-302. FIGHT-302 is a global, Phase III, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin … WebJToews19 • 8 yr. ago. I've taken both 300 and (math) 302. If you think you will ever need to do some stats in your career, STAT 300 would be extremely beneficial for you. The main …
FIGHT-302: First-line pemigatinib vs gemcitabine plus …
WebJul 22, 2024 · FIGHT-302: Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements. This study will compare chemotherapy (CisGem) with an FGFR-inhibitor in FGFR-altered patients and will require prior analysis of a tumour biopsy to determine that there is the appropriate FGFR … WebAug 19, 2024 · Here, the FIGHT-202 study showed that treatment with pemigatinib, a selective, ... (NCT03773302) with infigratinib and the FIGHT-302 study with pemigatinib (NCT03656536) for iCCA patients with ... init_process_group address already in use
FGFR Inhibitors Make Inroads in Cholangiocarcinoma - Targeted …
WebApr 1, 2024 · A randomized phase 3 study (FIGHT-302, NCT03656536) is currently evaluating the efficacy and safety of first-line pemigatinib versus gemcitabine plus cisplatin in patients with advanced CCA with FGFR2 rearrangements. 37 Recently, futibatinib (TAS-120), an irreversible FGFR1–4 inhibitor that binds covalently to a highly conserved P-loop ... WebOct 1, 2024 · Fibroblast growth factor receptor (FGFR) 2 alterations are implicated in CCA. Pemigatinib is a selective, potent, oral FGFR1, 2, and 3 inhibitor. We present data from a … WebFIGHT-302, a randomized, open-label, phase 3 study, will evaluate efficacy and safety of first-line pemigatinib vs gemcitabine + cisplatin in unresectable/metastatic … mnp country